Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Metabolic Syndrome Risk Among Adults Living with Sickle Cell Disease
source: American Society of Hematology
year: 2015
authors: Shawn M Bediako, Julie Nelson, Cody Cichowitz, Tiffany Yu, C. Patrick Carroll, Kerry J. Stewart, Rakhi P. Naik, Carlton Haywood Jr., Sophie Lanzkron
summary/abstract:Background: The life span of individuals living with sickle cell disease (SCD) has increased considerably over the past three decades. Yet, as this group ages, new concerns emerge about their overall health profile – particularly with regard to cardiovascular disease (CVD), the primary cause of mortality in the United States. Metabolic syndrome (MetS) is a cluster of conditions that are associated with a 2-fold increase in CVD outcomes and a 1.5-fold increase in all-cause mortality. Little is known, however, about the prevalence of MetS risk factors among adults with SCD. As part of exploring the CVD profile of this population, we report findings from a pilot study that sought to evaluate MetS (typically defined as the presence of 3 or more risk factors).
Methods: 49 adults (ages 21-66 years; 72% female) completed demographic and health behavior surveys, health-related family and personal histories, anthropometric measurements, the Block 2005 nutritional assessment, and a comprehensive blood panel. In terms of SCD genotype, 63% of participants were diagnosed with homozygous sickle cell anemia and 37% were diagnosed with hemoglobin SC disease. Descriptive and inferential statistics were used to summarize and compare MetS components stratified in separate analyses by genotype and sex.
Results: The most prevalent MetS risk factors observed in our study – large waist circumference and reduced HDL levels – affected 45% and 69% of the sample, respectively. Overall, 16% of participants met traditional criteria for MetS. Table 1 summarizes mean values and shows the gender-adjusted risk for MetS. Although 78% of the sample self-reported moderate to high physical activity, nearly half of participants were overweight and had dietary saturated fat intake levels that exceeded both the national average and US Dietary Guidelines (<10%). Participants with the SC phenotype were older, consumed more calories, and had higher BMI, waist circumference, and BP values compared to those with the SS phenotype. Overall, males had worse MetS risk profiles compared to women, but no statistically significant sex differences were observed with regard to components of MetS.
Conclusion: We report prevalence of MetS components, a surrogate of CVD risk, in a sample of adults living with SCD. Despite high levels of self-reported physical activity, both increased waist circumference and reduced HDL levels were notably high in our sample. These findings correspond with recent studies that indicate an upward trend in obesity and BMI among young adults with SCD. They also suggest a need to prioritize weight management, aerobic exercise, and resistance training strategies that could decrease MetS risk, but are rarely considered for this population.
organization: University of Maryland, Baltimore; Indiana University School of Medicine; Johns Hopkins University School of Medicine, Baltimore; University of Maryland School of Medicine, Baltimoreread more
Related Content
-
A Man With Sickle Cell Disease and HeadacheApproximately 17% of patients with sickl...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
-
Blood transfusions for treating acute chest syndrome in people with sickle cell diseaseBackground: Sickle cell disease is an...
-
Sickle Cell Trait and Risk of Cognitive Impairment in African Americans: The Reasons for Geographic and Racial Diffe...Background: Sickle cell anemia (SCA) has...
-
Retinopathy and sickle cellhttps://www.youtube.com/watch?v=i1awYgHl...
-
The Ways I Made Hydration a HabitWhen I was younger and didn’t have a f...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.